Michelle Gee

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text

Life Sciences, Neurology, Neuroscience +17

A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial ofParoxetine in Children and Adolescents With Social Anxiety Disorder

Karen Dineen Wagner, R.M.F. Berard, Murray B. Stein et al. · Archives of General Psychiatry · 2004 · 245 citations

Medicine, Pharmacology, Psychiatry +17

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck et al. · Alzheimer s Research & Therapy · 2024 · 145 citations · Full text

Medicine, Neurology, Pharmacology +17

Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial‐onset seizures: Interim results from phase III, extension study 307

Gregory L. Krauss, Emilio Perucca, E. Ben‐Menachem et al. · Epilepsia · 2012 · 116 citations

Medicine, Pharmacology, Pharmacotherapy +16

Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase <scp>III</scp> extension study 307

Gregory L. Krauss, Emilio Perucca, Elinor Ben‐Menachem et al. · Epilepsia · 2014 · 112 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16